Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhaseBio Pharmaceuticals Inc.

www.phasebio.com

Latest From PhaseBio Pharmaceuticals Inc.

Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe

Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.

Deals Business Strategies

Finance Watch: Hatteras Nearly Halfway To $200m Goal For New Early-Stage VC Fund

Private Company Edition: General Partner Clay Thorp says the venture capital firm's longtime focus on seed and early-stage investments is unchanged and bolstered by market fundamentals. Also, Talaris and insitro each raised $100m Series A rounds, plus other financings.

Financing StartUps and SMEs

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.

Financing Business Strategies

Keeping Track: NME Approvals For Evenity And Balversa; Non-NME Approvals For Dovato And Keytruda; But An RTF For Fintepla

The latest drug development news and highlights from our US FDA Performance Tracker. 
Drug Review Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Metabolic Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Phase Bioscience Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • PhaseBio Pharmaceuticals Inc.
  • Senior Management
  • Jonathan Mow, CEO
    John P Sharp, CFO
    Jim Ballance, PhD, VP, Rsch. & Scientific Affairs
    John S Lee, MD, PhD, CMO
    Michael B York, VP, Corp. Dev. & Commercial Strategy
  • Contact Info
  • PhaseBio Pharmaceuticals Inc.
    Phone: (610) 981-6500
    One Great Valley Pkwy., Ste. 30
    Malvern, PA 19355
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register